818-986-4356

Orbax

Antibiotic, Bactericidal, Fluoroquinolone, Hepatic enzyme inhibitor

Brand Names

Orbax®

Drug Information

Pharmacology

Fluoroquinolone antibiotic concentration dependent bactericidal.

Contraindications

General
  • Contraindicated in patients with known sensitivity to this type of drug.
  • Use with caution in patients with possible CNS disorders-may cause CNS stimulation and seizures.
  • Use only when benefit outweighs the risk during pregnancy as safety has not been established.
  • Administer orbifloxacin with caution in the presence of hepatic insufficiency/impairment.
General
  • WARNING: Extra label use in food animals is prohibited by the FDA.
Dog
  • Contraindicated in small and medium breed dogs 2 – 8 months old and large, giant breeds up to 1 year old due to the risk of articular cartilage damage.
Cat
  • DO NOT EXCEED 7.5 mg/kg BODY WEIGHT PER DAY IN CATS

Adverse Effects

General
  • Vomiting, loss of appetite, lethargy are possible side effects.
  • Anaphylactic reactions, facial swelling, ataxia and seizures are also possible.
  • Cartilage damage may occur-see contraindications.
Cat
  • The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. Blindness has also been reported post-approval in cats. In some cases, blindness has been temporary.
  • DO NOT EXCEED 3.4 mg/lb (7.5 mg/kg) BODY WEIGHT PER DAY IN CATS.

Interactions

General Interactions
  • Increased liver enzymes, BUN, creatinine and decreases in hematocrit have been reported in human taking fluoroquinolones. Clinical significance is unclear.

Category Interactions
Aminoglycoside Antibiotic
  • Synergism is possible but unpredictable with aminoglycosides.
Antacid
  • Antacids may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
Anticoagulant
  • Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.
Cephalosporin antibiotic
  • Synergism is possible but unpredictable with third generation cephalosporins.
Hepatic enzyme inhibitor
  • Metabolism of other cytochrome P-450 metabolized drugs may be altered.
Penicillin / related
  • Synergism is possible but unpredictable with certain penicillins.

Drug Interactions
Aminophylline
  • If given concurrently, may increase serum levels of theophylline.
CycloSPORINE
  • Fluoroquinolones may increase the risk of nephrotoxicity from systemic CycloSPORINE.
Nitrofurantoin
  • Nitrofurantoin may antagonize activity of orbifloxacin.
Sucralfate
  • Sucralfate may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
Theophylline
  • May inhibit theophylline metabolism and result in toxicity.

Comments

WARNING: Extra label use in food animals is prohibited by the FDA.
Oral suspension does not require refrigeration – shake well before use.

Available Forms

Human
  • None
Veterinary – General
  • Tablets- 5.7 mg in btls of 250 tabs, 22.7 mg in btls of 250 and 68 mg in btls of 100; Orbax® Approved for dog and cat. Oral suspension – in 20 mL bottles; ORBAX® Oral Suspension. Approved for dog and cat.

Analytics Plugin created by Web Hosting